MAPT and tauopathy: For instance, a recent work described the development of a tau dephosphorylating-targeting chimera (DEPTAC) and produced a novel chimera D14, which demonstrated minimal cytotoxicity and excellent efficacy in lowering tau phosphorylation in both cell and tauopathy mice models.